• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Director Zane Ellen M was granted 2,693 shares, increasing direct ownership by 16% to 19,373 units (SEC Form 4)

    7/25/25 4:36:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care
    Get the next $HAE alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Zane Ellen M

    (Last) (First) (Middle)
    125 SUMMER STREET

    (Street)
    BOSTON MA 02110

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HAEMONETICS CORP [ HAE ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/24/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 07/24/2025 A 2,693(1) A (2) 19,373 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The securities awarded are in the form of restricted stock units ("RSUs") issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant.
    2. Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
    /s/ Thomas V. Powers, attorney-in-fact for Ms. Zane 07/25/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HAE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HAE

    DatePrice TargetRatingAnalyst
    8/11/2025$78.00Strong Buy → Outperform
    Raymond James
    8/8/2025$62.00Overweight → Neutral
    Analyst
    8/8/2025$95.00 → $86.00Outperform
    Barrington Research
    7/9/2025$90.00Neutral → Buy
    Citigroup
    6/26/2025$87.00Outperform
    Robert W. Baird
    2/7/2025$95.00 → $68.00Neutral → Underperform
    BofA Securities
    12/6/2024$116.00Overweight
    Analyst
    11/8/2024$120.00Outperform → Strong Buy
    Raymond James
    More analyst ratings

    $HAE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Zane Ellen M was granted 2,693 shares, increasing direct ownership by 16% to 19,373 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:36:13 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Pomeroy Claire was granted 2,693 shares, increasing direct ownership by 19% to 16,872 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:33:39 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Director Kroll Mark W was granted 2,693 shares, increasing direct ownership by 13% to 23,357 units (SEC Form 4)

    4 - HAEMONETICS CORP (0000313143) (Issuer)

    7/25/25 4:30:46 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Vivasure Medical Submits PMA Application for PerQseal® Elite and Secures Expanded Venous Indication in Europe

    Regulatory progress underscores global momentum for PerQseal Elite in transforming large-bore vascular closure Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the submission of a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its PerQseal® Elite vascular closure system for arterial procedures. The submission builds upon the successful results of the PATCH study as well as positive clinical use in Europe, reinforcing the system's potential safety and performance profile. In addition, the company received European CE mark approval for an expanded indication for PerQseal Elite

    6/24/25 8:00:00 AM ET
    $HAE
    $OBIO
    Medical/Dental Instruments
    Health Care
    Medicinal Chemicals and Botanical Products

    $HAE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Haemonetics downgraded by Raymond James with a new price target

    Raymond James downgraded Haemonetics from Strong Buy to Outperform and set a new price target of $78.00

    8/11/25 9:46:26 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics downgraded by Analyst with a new price target

    Analyst downgraded Haemonetics from Overweight to Neutral and set a new price target of $62.00

    8/8/25 8:19:52 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Haemonetics with a new price target

    Barrington Research reiterated coverage of Haemonetics with a rating of Outperform and set a new price target of $86.00 from $95.00 previously

    8/8/25 7:34:13 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    SEC Filings

    View All

    SEC Form 10-Q filed by Haemonetics Corporation

    10-Q - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:08:06 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    8/7/25 6:04:03 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - HAEMONETICS CORP (0000313143) (Filer)

    7/25/25 4:16:54 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Financials

    Live finance-specific insights

    View All

    Haemonetics 1st Quarter Fiscal Year 2026 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, Aug. 7, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its first quarter fiscal year 2026, which ended June 28, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on August 7, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BIb1de2bd7b8b

    8/7/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2026 Results: August 7, 2025

    BOSTON, July 9, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish first quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, August 7, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on August 7, 2025. The call can be accessed via teleconference at: Q1 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. W

    7/9/25 4:05:00 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website

    Financial release accessible online BOSTON, May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m. ET on May 8, 2025. The conference call and webcast can be accessed with the following information: Teleconference link:https://register-conf.media-server.com/register/BI8b22e12b2

    5/8/25 6:00:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Leadership Updates

    Live Leadership Updates

    View All

    Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

    9/24/24 8:00:00 AM ET
    $ALGS
    $HAE
    $NVO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    Sotera Health Appoints Christopher Simon to the Board of Directors

    CLEVELAND, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Christopher Simon as a new independent director to its Board of Directors. Mr. Simon will serve as a member of the Leadership Development and Compensation Committee of the Board of Directors. For approximately the past eight years, Mr. Simon has served as the President and Chief Executive Officer of Haemonetics Corporation (NYSE:HAE), a global medical technology company, as well as a member of Haemonetics' Board of Directors. Previ

    8/1/24 7:00:02 AM ET
    $HAE
    $SHC
    Medical/Dental Instruments
    Health Care
    Misc Health and Biotechnology Services

    Haemonetics Appoints Roy Galvin as President, Global Plasma and Blood Center

    BOSTON, Oct. 4, 2022 /PRNewswire/ -- Haemonetics Corporation (NYSE:HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced the appointment of Roy Galvin as President, Global Plasma and Blood Center, effective October 10, 2022. He will report to Chris Simon, Haemonetics' President and Chief Executive Officer. As President of Haemonetics' Global Plasma and Blood Center business units, Galvin will have responsibility for driving the Company's transformational growth objectives and advancing the

    10/4/22 6:51:00 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    $HAE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Haemonetics Corporation

    SC 13G - HAEMONETICS CORP (0000313143) (Subject)

    11/14/24 1:28:29 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/12/24 12:54:20 PM ET
    $HAE
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Haemonetics Corporation

    SC 13G/A - HAEMONETICS CORP (0000313143) (Subject)

    11/8/24 10:41:07 AM ET
    $HAE
    Medical/Dental Instruments
    Health Care